EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

NCT07339527 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Mature T-cell and NK-cell Lymphoma

Interventions

DRUG: Zeprumetostat
DRUG: Golidocitinib
DRUG: Chidamide

Sponsor

Sun Yat-sen University